Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide Plus Capecitabine in Grade 3 Low Ki-67 GEP-NETs
NCT03079440Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- May 2017
- Primary completion
- Nov 2020
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and capecitabine in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Asan Medical Center. Primary endpoint: Response rate at 2 years. Started May 2017; status: completed.
02
Drugs
temozolomidecapecitabine
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT03079440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03079440.